A Study of RO5028442 in Adult Male High-Functioning Autistic Patients
Status:
Completed
Trial end date:
2013-03-01
Target enrollment:
Participant gender:
Summary
This multi-center, randomized, double-blind study will evaluate exploratory biomarkers and
the safety and tolerability of a single dose of RO5028442 in adult male high-functioning
autistic patients. In a cross-over design, patients will be randomized to receive either a
single dose of RO5028442 or matching placebo with a washout period of 7-14 days. Anticipated
time on study is up to approximately 9 weeks.